Alvogen is an international pharmaceutical company focusing on the manufacture, development and marketing of generic pharmaceuticals, biosimilars and over-the-counter products (OTCs).
Founded in 2009, Alvogen is young at heart and full of vitality. We are also based on rich tradition, as Alvogen acquired the 125-year-old Norwich Pharmaceuticals soon thereafter.
Alvogen has offices in over 30 countries and more than 200 pharmaceutical projects in various stages of development and registration. The largest market today is in North America, where we have 500 employees working at Norwich pharmaceuticals.
Our chairman and CEO is Robert Wessman who also leads our global expansion, along with our excellent leadership team, known for its outstanding track record.